The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment (T) of T2 N0-1 larynx cancer (LC) with hyperfractionated radiotherapy (HRT) and cetuximab (C): Final report.
R. E. Giglio
Honoraria - Merck Serono
Other Remuneration - Merck Serono
A. Navigante
No relevant relationships to disclose
M. D. Pereira
No relevant relationships to disclose
L. Califano
No relevant relationships to disclose
B. M. C. Roth
No relevant relationships to disclose
P. Saco
No relevant relationships to disclose
M. A. Castro
No relevant relationships to disclose
P. Menendez
No relevant relationships to disclose
P. Aguerre
No relevant relationships to disclose
R. Adan
No relevant relationships to disclose
C. Brosio
No relevant relationships to disclose
C. Pogany
No relevant relationships to disclose